Related Experiment Video
Updated: Jul 9, 2026
09:04
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Antisense oligonucleotides in cancer: recent advances
1Dept of Medicine, Columbia University, College of Physicians & Surgeons, New York, New York 10032, USA.
Summary
Antisense nucleic acids offer novel cancer therapy by targeting oncogenes and tumor suppressor genes. While challenges exist in target selection and controlling nonspecific effects, several antisense drugs show promise in clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer arises from genetic alterations like oncogene activation and tumor suppressor gene inactivation.
- Antisense nucleic acids represent a therapeutic strategy to modulate gene expression and combat malignant cell behavior.
- Identifying optimal antisense targets remains a significant challenge in developing effective cancer therapies.
Purpose of the Study:
- To review the potential of antisense nucleic acids as a cancer therapy.
- To discuss promising gene targets for antisense-based cancer treatment.
- To highlight advancements and challenges in the development of antisense drugs for cancer.
Main Methods:
- Review of existing literature on antisense technology in cancer therapy.
- Identification and discussion of extensively studied antisense targets (e.g., proteases, telomerase, kinases).
- Analysis of strategies for combining antisense oligonucleotides with cytotoxic agents and the importance of control oligonucleotides.
Main Results:
- Several promising targets for antisense cancer therapy have been identified and studied.
- Antisense oligonucleotides have demonstrated efficacy in in vitro experiments and progressed to clinical trials.
- Next-generation antisense drugs with structural modifications are under development.
Conclusions:
- Antisense nucleic acids hold significant potential for targeted cancer therapy.
- Careful selection of targets and control strategies are crucial for therapeutic success.
- Ongoing development of advanced antisense drug generations promises improved efficacy and safety.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...